Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1976 - BRAF-mutated colorectal metastases: what is the benefit of liver surgery? Results from a cohort of 91 patients.


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Sahir Javed


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


S. Javed1, S. Benoist2, C. de la Fouchardiere3, S. Truant4, D. Sefrioui5, M.P. Galais6, V. Hautefeuille7, P. Artru8, R. Guimbaud9, R. Cohen10, A. Lievre11, J. Edeline12, J. Bachet13, M. Gelli14, A. Herrero15, U. Marchese16, M. El Amrani17, P. Devos18, A. Turpin1, A. Ploquin1

Author affiliations

  • 1 Medical Oncology, Hopital Claude Huriez, Lille University Hospital, 59037 - Lille/FR
  • 2 Digestive Surgery, Le Kremlin-Bicêtre, 94275 - Le Kremlin-Bicêtre/FR
  • 3 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 4 Digestive Surgery, Hopital Claude Huriez, Lille University Hospital, 59037 - Lille/FR
  • 5 Digestive Oncology, CHU Hôpitaux de Rouen-Charles Nicolle, 76031 - Rouen/FR
  • 6 Digestive Oncology, Centre Francois Baclesse, 14076 - Caen/FR
  • 7 Gastroenterology And Digestive Oncology, CHU Amiens-Picardie Site Nord, 80054 - Amiens/FR
  • 8 Gi Oncology, Hôpital privé Jean Mermoz, 69373 - Lyon/FR
  • 9 Oncology, Toulouse-Rangueil University Hospital, 31059 - Toulouse/FR
  • 10 Medical Oncology Department, Hôpital Saint-Antoine, 75571 - Paris/FR
  • 11 Digestive Oncology, CHU de Pontchaillou, 35033 - Rennes/FR
  • 12 Digestive Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 13 Digestive Department, Groupe Hospitalier Pitié Salpetriere, 75013 - Paris/FR
  • 14 Visceral And Oncological Surgery, Gustave Roussy, Villejuif cedex/FR
  • 15 Digestive Surgery, University Hospital Center, University of Montpellier-Nîmes, 34090 - Montpellier/FR
  • 16 Surgery, Institut Paoli-Calmettes, Marseille/FR
  • 17 Digestive Surgery, Huriez hospital, 59037 - Lille/FR
  • 18 Biostatistic Unit, Lille University Hospital, Lille/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1976


BRAF V600E-mutated colorectal liver metastases (CRLM) are associated with higher relapse rate and shorter survival time after resection as compared to BRAF wild-type CRLM. It remains unsure whether metastatic surgery has a benefit over chemotherapy alone in this setting. To address this question, we analyzed a large cohort of BRAF-mutated CRLM patients in order to evaluate the impact of liver surgery on overall survival (OS).


We retrospectively identified BRAF-mutated colorectal cancers diagnosed with liver-only metastases (n = 91) resected or not from October 1, 2003 to December 31,2017 in 24 French centers. The impact of CRLM resection on OS (primary endpoint) was analyzed by Kaplan-Meier method and Cox model. OS was defined from the time of CRLM diagnosis to death from any cause. Progression free survival (PFS) was defined from the time of first chemotherapy (even for resected patients) to first progression or death.


Ninety-one patients were included: 43 (47%) with resected CRLM and 48 (53%) treated with chemotherapy only. Among resected CRLM, 34 (79%) received chemotherapy before surgery. BRAF V600E mutation was detected in 83 (91%) patients and non-V600E mutation in 8 (9%) patients. In comparison to resected CRLM, unresected CRLM were more often bilobar (76% versus 51%, p = 0.03) and greater than 5 (62% versus 34%, p = 0.02). There was no statistical difference in the other criteria especially in rates of synchronous metastases (94% versus 81%, p = 0.11). Median OS was 32.1 months for resected patients and 11.4 months for unresected patients (p < 0.0001). In univariate analysis, 4 parameters were statistically associated with poor OS: rectum primary site (p = 0.002), greater than 5 (p = 0.018), BRAF V600E mutation (p = 0.010) and no liver surgery (p < 0.0001). In multivariate analysis, liver surgery was the only variable associated with significant longer OS (hazard ratio [HR]= 0.125, CI 95%: 0.068 – 0.229, p < 0.0001) and PFS (HR = 0.173, CI 95% 0.101 – 0.296, p < 0.0001).


To our knowledge, this is the largest cohort of colorectal cancer with liver-only metastases harboring BRAF V600E mutation. Liver surgery extend significantly OS and therefore CRLM resectability should be assessed in BRAF-mutated colorectal cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Ploquin, Anne.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.